Ironwood Pharmaceuticals
IRWD
212 hedge funds and large institutions have $676M invested in Ironwood Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 73 increasing their positions, 84 reducing their positions, and 36 closing their positions.
19% more capital invested
Capital invested by funds: $567M → $676M (+$109M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.51% less ownership
Funds ownership: 99.04% → 97.53% (-1.5%)
7% less funds holding
Funds holding: 227 → 212 (-15)
13% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 84
33% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 36
49% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $3.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.1M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$6.97M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.21M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4.42M |
| 5 |
Morgan Stanley
New York
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$5.53M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.18M |
| 3 |
Two Sigma Investments
New York
|
-$4.98M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.79M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$4.5M |
IRWD Hedge Fund Activity: Q2 2026 in Review
212 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2026, worth a combined $676M — up 19% from $567M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of IRWD and 24 opened new positions — a net loss of 12 holders — while 84 trimmed existing stakes and 73 added.
The largest buyer was BlackRock, adding an estimated $17.1M. The largest seller was Charles Schwab, cutting an estimated $5.53M.
- 212 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2026, down from 227 in Q1 2026.
- Funds reported $676M of Ironwood Pharmaceuticals stock for Q2 2026, up 19% quarter-over-quarter.
- 24 funds opened new Ironwood Pharmaceuticals positions in Q2 2026 and 36 closed out, a net change of -12 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $17.1M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2026 was Charles Schwab, an estimated $5.53M sold.
Based on aggregated 13F filings for Q2 2026.